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ABSTRACT Almost all homosexual patients with acquired
immunodeficiency syndrome are also actively infected with
human cytomegalovirus (HCMV). We have hypothesized that
an interaction between HCMV and human immunodeficiency
virus (HIV), the agent that causes acquired immunodeficiency
syndrome, may exist at a molecular level and contribute to the
manifestations ofHIV infection. In this report, we demonstrate
that the immediate-early gene region of HCMV, in particular
immediate-early region 2, trans-activates the expression of the
bacterial gene chloramphenicol acetyltransferase that is fused
to the HIV long terminal repeat and carried by plasmid
pHIV-CAT. The HCMV immediate-early trans-activator in-
creases the level of mRNA from the plasmid pHIV-CAT. The
sequences of HIV that are responsive to trans-activation by the
HCMV immediate-early region are distinct from HIV se-
quences that are required for response to the HIV tat. The
stimulation of HIV gene expression by HCMV gene functions
could enhance the consequences of HIV infection in persons
with previous or concurrent HCMV infection.
Human cytomegalovirus (HCMV) is a herpesvirus that com-
monly infects patients with acquired immunodeficiency syn-
drome (AIDS) (1). Like human immunodeficiency virus
(HIV), it can be transmitted by sexual intercourse and blood
transfusion (2). More than 95% of a major group at risk for
AIDS, homosexual men, are seropositive for HCMV, and
many actively shed virus (3). Even in apparently healthy
homosexual men, 30% of semen samples yield HCMV on
culture (3).
HCMV infects a number of different cell types including
lymphocytes (4). HCMV and HIV may, therefore, target the
same cells. Furthermore, an elevated titer of cytomegalovi-
rus antibody is a significant predictor of the development of
AIDS in HIV-seropositive homosexual men (5). For these
reasons, we decided to explore the possibility of an interac-
tion between the two viruses at the molecular level.
The transcription of HIV is subject to complex regulation
(6). The proviral genome has a single promoter located within
the 5'-long terminal repeat (LTR) that is trans-activated by
the HIV-encoded gene tat (trans-activating transcriptional
activator). Sequences located on the 3' side of the mRNA
start site, termed TAR, are necessary for trans-activation by
tat to occur (7).
We have examined the ability of the HCMV immediate-
early (IE) gene region to trans-activate the HIV promoter.
The HCMV IE region, located on the HCMV genome
between 0.66 and 0.75 map units, encodes the first group of
genes to be expressed after HCMV infection of cells. Several
different proteins could be encoded within the HCMV IE
region (8) (Fig. 1). generated by alternative splicing within IE
regions 1 and 2. We show selective expression of these
alternate splicing domains and various effects of these gene
products on the gene expression downstream from target
promoters.
In this report, we demonstrate that the HCMV IE gene
region stimulates expression ofthe bacterial chloramphenicol
acetyltransferase (CAT) gene linked to the HIV promoter
(pHIV-CAT). We show that the HIV promoter sequences
necessary for trans-activation by the HCMV IE gene region
are different from those required for stimulation by tat. We
find that the region 2 sequences of the HCMV IE region are
required for trans-activation of the HIV promoter indepen-
dent ofthe major product ofIE region 1. In addition, we show
that trans-activation by the HCMV IE region is associated
with an increased level of pHIV-CAT mRNA.
MATERIALS AND METHODS
Construction of HCMV Plasmids. Four HCMV IE region
plasmids were constructed. In pHD101SV1, the region 1 and
region 2 of the HCMV IE region are under the control of the
HCMV IE promoter with the simian virus 40 (SV40) enhanc-
er located further upstream. To construct plasmid pHD101-
SV1 (Fig. 1), the EcoRI fragment of the HCMV genome from
0.72 to 0.76 map units was inserted into the EcoRI site of
plasmid pSVOH (10). The second HCMV plasmid, pHD-
101SV2, is identical to pHD101SV1 except that the 5.5-
kilobase (kb) BamHI fragment containing region 2 has been
deleted. All of the protein-coding sequences were deleted
from plasmid pHD1O1SV1 by digestion with enzymes Sst I
and BamHI to generate plasmid pHD1O1SVO.
The exon sequences of the HCMV IE regions 1 and 2 were
recombined into two other plasmid constructions, illustrated
in Fig. 1. The third HCMV IE plasmid, pHD1O1SV3, was
constructed by inserting three separate DNA fragments into
the multiple cloning site of plasmid pGEM2 (Promega Biotec,
Madison, WI). A 2.1-kb Pst I fragment containing the HCMV
region 1 promoter-enhancer, first exon, intron, and splice
acceptor was positioned upstream from the 5.5-kb BamHI
fragment carrying HCMV IE region 2 and downstream from
a 1.1-kb HindIII fragment carrying the SV40 early promoter.
This plasmid is similar to plasmid pHD101SV1, but all of the
sequences coding for the major IE product are deleted.
The fourth HCMV IE plasmid, pHD101-4, was constructed
by recombining two DNA fragments into the multiple cloning
site of plasmid pUC18 (Fig. 1A, line e). A 2-kb Taq I fragment
containing the HCMV region 1 promoter-enhancer and first
three exons of region 1 (and not the fourth exon) was inserted
Abbreviations: HCMV, human cytomegalovirus; AIDS, acquired
immunodeficiency syndrome; HIV, human immunodeficiency virus;
LTR, long terminal repeat; IE, immediate-early; CAT, chloramphen-
icol acetyltransferase; SV40, simian virus 40.
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FIG. 1. Construction of plasmids containing HCMV or HIV ge-
nomic segments. (A) Construction of plasmids containing HCMV
DNA. Line a shows the fractional length of the HCMV genome. Line
b shows plasmid pHD1O1SV1. Plasmid sequences derived from
pBR322 (open box) and RNA transcripts corresponding to HCMV IE
regions 1 and 2 (closed boxes) are illustrated right to left. B, BamHI; R,
EcoRI. Line c shows plasmid pHD1O1SV2. The BamHI fragment from
region 2 of pHD101SV1 has been deleted to form pHD1O1SV2. Line d
shows plasmid pHD101SV3. The BamHI fragment from region 2 of
pHD101SV1 has been inserted downstream from the SV40 early
promoter and the Pst I fragment containing the promoter, first exon,
intron, and splice acceptor ofregion 1. The amino acid coding sequence
of the major IE protein has been deleted. Line e shows plasmid
pHD1014. The BamHI fragment from region 2 of pHD1O1SV1 was
inserted downstream from the Taq I fragment containing the promoter
and first three exons of IE region 1. Q, Taq I. Line f shows plasmid
pHD1O1SVO. All ofthe eukaryotic protein-coding sequences have been
deleted, leaving the SV40 promoter-enhancer and the HCMV IE
promoter-enhancer sequences between 1200 and 17 bases preceding the
mRNA start site. S, Sst I. Line g shows plasmid pHD1O1CAT2.
Stippled box, bacterial CAT gene. This plasmid has the HCMV IE
promoter (positions -523 to +97 relative to the mRNA start site) fused
to the bacterial CAT gene. T, Tha I. (B) Construction of plasmids
containing HIV DNA. Line a shows the HIV genome. Numbers are in
kb from the RNA initiation site at zero. Solid boxes, open reading frame
coding for tat (9); vertical-lined boxes, LTR sequences. Line b shows
plasmid pBENN-2 (9). Hatched box, human genomic segments not
derived from HIV. The last 1000 bases of HIV are deleted. V, EcoRV;
H, Hind.I1; Sa, Sal I. Line c shows pHIV-CAT. Numbers indicate the
nucleotides upstream (position -342) and downstream (position +77) of
the mRNA initiation point contained within the HIV insert. TAR,
trans-activating responsive sequence (7). The direction of transcription
is illustrated left to right. Line d shows pHIVACAT. Numbers indicate
the nucleotides upstream (position -342) and downstream (position
+29) ofthe RNA initiation point contained within the HIV DNA insert.
This plasmid lacks response to tat because the TAR sequence is deleted.
Line e shows pBENN-2-SOR. The last 2.7 kb ofpBENN-2 are deleted.
This plasmid does not encode the HIV tat, but it carries the HIV LTR
and sor. Line f shows pHD1O1TAT. The 2.7-kb fragment isolated from
pBENN-2 was recombined downstream from the Pst I fragment of
HCMV IE region 1 described in A, line d. This plasmid carried HIV tat
between nucleotides 5366 and 8052 of HIV and HCMV sequences
between nucleotides -1200 and + 1000 relative to the mRNA start site.
Note that the direction of transcription as illustrated is left to right,
opposite from the direction illustrated in A, lines a-g. P. Pst I.
upstream from the 5.5-kb BamHI fragment carrying HCMV
IE region 2 sequences. The plasmids pHD1O1SV3 and pHD-
1014 contain IE exon sequences in combinations that are
observed to be spliced together in RNAs from infected cells
(8). In addition, the last HCMV plasmid, pHD1O1CAT2, was
constructed in which the HCMV IE promoter (positions
-523 to +97 relative to the major mRNA start site) is fused
to the bacterial CAT gene.
HIV Plasmids. The plasmid pHIV-CAT contains HIV LTR
sequences (positions -342 to +77 relative to the mRNA start
site), including the tat-responsive sequence, fused to the
bacterial CAT gene (Fig. 1). The plasmid pHIVACAT is
identical to pHIV-CAT except that the tat-responsive se-
quence from positions +29 to +77 (Sst I site to HindIII site)
has been deleted, so that the plasmid is no longer responsive
to the HIV tat.
HIV tat activity was obtained using plasmid pBENN-2 (a
gift from Malcolm Martin, National Institutes of Health),
which contains the HIV sequences from the 5' LTR to
position 8053. This plasmid thus encodes a functional tat (9).
The amino acid coding region of tat is included in a 2.7-kb
DNA fragment generated by digestion of pBENN-2 with
enzymes Sal I and BamHI. This region was deleted from
pBENN2 to generate plasmid pBENN-2-SOR, which con-
tains the sor coding region of HIV but not tat. The isolated
2.7-kb HIV DNA fragment containing the coding sequences
for tat was recombined downstream from the HCMV IE
region 1 promoter-enhancer in plasmid pHD1O1TAT (Fig. 1).
This plasmid expresses the HIV tat in the absence of other
HIV genes.
The plasmid pCAT3M (a gift from George Khoury, Na-
tional Institutes of Health) contains the bacterial CAT gene
but no eukaryotic promoter elements.
The plasmid pRSVCAT (a gift from Bruce Howard, Na-
tional Institutes of Health) contains the bacterial CAT gene
fused to the Rous sarcoma virus LTR sequences from
positions -489 to +33 relative to the mRNA start site (11).
Transfection of Cells. HeLa cells were transfected with
calcium phosphate-precipitated plasmid DNA (12) followed
by glycerol shock treatment. BJAB cells were transfected by
electroporation with a Zapper electroporation unit (Univer-
sity of Wisconsin Medical Electronics Lab, Madison, WI) at
1500 V. Cells and plasmid DNA were mixed in 0.5 ml of
growth medium and transferred to a 1 cm x 1 cm plastic
cuvette to which aluminum electrode strips were glued. After
voltage was applied to the samples, the cells were diluted into
medium and incubated at 370C in an atmosphere of 5%
C02/95% air.
CAT Assays. Cell extracts were prepared and assayed as
described (11). ['4C]Chloramphenicol (0.2 1uCi; 1 Ci = 37
GBq) was incubated with 0.7 mM acetyl coenzyme A and 100
1.l of cell extract in a final volume of 120 1.l of0.25 M Tris-HCI
(pH 7.8) for 60 min at 370C. Radioactive materials were
extracted with ethyl acetate and separated by chromatogra-
phy on thin layer plates. The percentage of chloramphenicol
converted to acetylated forms was determined for each
sample.
RNA Isolations. Total cellular RNA was isolated from
BJAB cells by a modification of the method described by
Favaloro et al. (13). Cells (108 cells) were centrifuged and
lysed with solution containing 0.25% Nonidet P-40, 1%
NaDodSO4, 10 mM EDTA, and proteinase K at 200 ,ug/ml.
Nucleic acids were precipitated with alcohol and resuspend-
ed in 300 1.l of buffer containing 10 tug of DNase (Promega
Biotec). After digestion for 30 min at 370C, the RNA was
purified by phenol/chloroform extraction and ethanol pre-
cipitation.
S1 Nuclease Analysis. For S1 nuclease analysis of RNA
transcripts, a portion of the pHIV-CAT plasmid (including
the entire HIV promoter plus 250 base pairs of the CAT
r<zzzzzzzzzzzzzzz
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sequence) was cloned into the pGEM2 (Promega Biotec)
vector next to the SP6 polymerase promoter. A uniformly
32P-labeled antisense RNA probe was synthesized using SP6
polymerase. Total cellular RNA (35 tkg) was hybridized with
the RNA probe (6.5 x 104 cpm). The single-stranded material
was digested with S1 nuclease, and the nuclease-protected
RNA was analyzed on a 6% acrylamide gel containing 7 M
urea.
RESULTS
The HCMV IE Region Trans-Activates pHIV-CAT. To
assess the effect of the HCMV IE region on HIV promoter
function, 10 tkg of the pHIV-CAT plasmid was cotransfected
into HeLa cells with either 10 ,ug of the pHD1O1SVO plasmid
(which contains the SV40 enhancer and HCMV promoter but
no HCMV IE coding sequences) or with 10 ,ug of the
pHD1O1SV1 plasmid (which has the region 1 and region 2 of
the HCMV IE region under the control of the HCMV
promoter and SV40 enhancer). Alternatively, the pHIV-CAT
plasmid was cotransfected with the pBENN-2 plasmid,
which encodes the HIV tat.
The results of these cotransfection experiments are shown
in Fig. 2 and listed in Table 1. As expected, the pBENN-2
plasmid, which encodes tat, dramatically increases the CAT
activity of pHIV-CAT (70- to 300-fold stimulation in a
number of separate experiments). The HCMV IE gene region
also increases pHIV-CAT activity (28- to 117-fold stimulation
in several different experiments), although the degree of
transactivation is generally not as great as that obtained with
the pBENN-2 plasmid. When both the pBENN-2 and the
pHD1O1SV1 plasmids were cotransfected together with
pHIV-CAT, the effect was additive (see Table 1 and Fig. 2)
rather than synergistic. Neither the HCMV IE promoter













FIG. 2. Effect of HCMV IE gene products on the HIV promoter.
HeLa cells were transfected with calcium phosphate-precipitated
plasmid DNA. Samples contained (i) pCAT3M plasmid (20 ,ug), (ii)
pHIVCAT plasmid (20 ,ug), (iii) pHIVCAT (10 ,ug) and 10 ,zg of
trans-activator plasmid pBENN-2 (contains HIV tat), (iv) pHIVCAT
(10 ug) and 10 ,ug of plasmid pHD101SV1 (contains HCMV IE
regions 1 and 2), or (v) pHIVCAT (10 jhg), pHD101SV1 (5 ttg), and
pBENN-2 (5 ,ug). Forty-eight hours after transfection, cell extracts
were incubated with ['4C]chloramphenicol and acetyl coenzyme A.
Radioactive products were separated by TLC and detected by
autoradiography. A 24-hr exposure is shown, indicating the relative
stimulation ofpHIV-CAT by the HIV tat, the HCMV IE region, and
the additive effect of both trans-activators.
2-SOR, which does not encode tat, stimulated the activity of
pHIV-CAT.
The plasmid pHD1O1SV1 does not stimulate CAT activity
when cotransfected with the promoterless vector plasmid
pCAT3M. The effect of the HCMV IE region was also tested
using the promoter of the Rous sarcoma virus. In contrast to
the trans-activating effect seen when pHD1O1SV1 is cotrans-
fected with the pHIV-CAT plasmid, there is not a significant
stimulatory effect observed when pHD1O1SV1 is cotrans-
fected with pRSV-CAT, which has the CAT gene fused to the
Rous sarcoma virus promoter (11) (data not shown). Thus,
the HCMV IE gene region encodes a trans-activator that
stimulates the activity of the HIV promoter but does not
significantly stimulate the promoter of another retrovirus
(Rous sarcoma virus).
The HCMV IE Gene Region Decreases the Activity of the
HCMV IE Promoter. The effect of the HCMV IE gene region
was also tested in cotransfection experiments with the
plasmid pHD1O1CAT2, which contains the HCMV IE pro-
moter fused to the CAT gene. Cotransfection of pHD101-
CAT2 with the plasmid pHD1O1SV1, which contains both
regions 1 and 2 of the HCMV IE region, decreased the
activity of the HCMV IE promoter by a factor of 8 (Fig. 3).
Thus, the HCMV IE region down-regulates the activity of its
own promoter.
The Region 2 of HCMV IE Gene Region Is Required for
Trans-Activation of pHIV-CAT. To ascertain whether region
1 and region 2 of the HCMV IE region are both required for
trans-activation ofpHIV-CAT, we cotransfected the plasmid
pHD1O1SV2, which has the region 2 deleted but still encodes
region 1, with pHIV-CAT. The region 1 products alone were
not sufficient to trans-activate the pHIV-CAT plasmid (Table
1). Thus, a region 2-encoded gene product must be required
for stimulation of the HIV promoter. In contrast, the region
1 alone, carried by plasmid pHD1O1SV2, was sufficient to
down-regulate the HCMV IE promoter (Fig. 3). Cotransfec-
tion of pHD1O1CAT2 with the plasmid pHD1O1SV2 de-
creased CAT activity by a factor of 8. Therefore, the
stimulatory effect and down-regulating effect of the HCMV
IE gene region may be encoded by separate domains of the
HCMV IE gene region.
The HCMV IE region 2 expression plasmids were tested
for the ability to trans-activate pHIV-CAT in the absence of
the major product from HCMV IE region 1. Cotransfection
of pHIV-CAT and plasmid pHD1O1SV3 resulted in an 8-fold
higher enzyme activity over transfection with plasmid pHD-
lOiSVO, and cotransfection of the fourth HCMV IE plasmid,
pHD101-4, resulted in 95-fold higher activity (Fig. 4). This
corresponds to the full stimulation observed with plasmid
pHD1O1SV1. The average stimulation in several experiments
is listed in Table 1. Thus, all of the trans-activation activity
of the HCMV IE regions 1 and 2 is carried by plasmid
pHD101-4.
Plasmids pHD1O1SV3 and pHD101-4 do not encode the
HCMV major IE protein and cotransfection with HCMV
plasmid pHD1O1CAT2 does not show down-regulation of the
major IE promoter.
The HIV tat-Responsive Sequences Are Not Required for
Trans-Activation by the HCMV IE Gene Region. The HIV
promoter region is not responsive to transactivation by tat
unless the tat-responsive sequence, located on the 3' side of
the mRNA start site, is present. We constructed the plasmid
pHIVACAT, which has the tat-responsive sequence deleted,
to determine if this sequence is also necessary for trans-
activation by the HCMV IE gene region. As expected,
pHIVACAT is not stimulated by cotransfection with the
plasmid expressing HIV tat (Table 1). However, note that the
HCMV IE gene region (carried by plasmids pHDiO1SV1 and
pHD101-4) continues to trans-activate the HIV promoter
even when the tat-responsive sequence has been deleted.
Proc. Natl. Acad. Sci. USA 84 (1987)
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Table 1. Effect of the HCMV IE region and HIV tat on CAT expression
Trans-activator plasmid Trans-activating protein CAT activity
Exp. specified pHIV-CAT pHIVACAT
1 pHD101SVO None 0.28% [0.13-0.7%] 1.5% [0.08-3%]
pHD1O1SV1 HCMV IE 1 and 2 7.8% [4-25%] (28) 10.5% [0.5-39o] (7)
pHD1O1SV2 HCMV IE 1 0.29% [0.2-0.5%] (1) 1.5% [0.09-3%] (1)
pHD101SV3 HCMV IE 2 1.4% [0.5-2.3%] (5)
pHD101-4 HCMV IE 2 11.0% [5-27%] (40) 9.0% [0.9-14%] (6)
pHD1O1TAT HIV tat 43.06% [20-54%] (150) 0.9%o [0.5-1.4%] (0.6)
2 pHD1O1SVO None 0.4% [0.2-1%]
pHD1O1SV1 HCMV IE 1 and 2 11.0% [5-21%] (29)
pBENN-2 HIV tat and sor 31.0%o [16-62%] (78)
pBENN-2-SOR HIV sor 0.6% [0.5-1%] (1.5)
pHD1O1SV1 plus pBENN-2 HCMV IE 1, 2, and HIV tat 41.0% [15-60%o] (103)
Indicator plasmid (10 ,ug) was cotransfected with 10 jig of the trans-activating plasmid into HeLa cells. CAT activity was measured 48 hr after
transfection as described (11). The trans-activating effect in this table is expressed as the percent acetylation of chloramphenicol in a standard
assay. The numbers represent an average of several experiments, and the range of these determinations is indicated in brackets. The fold
stimulation of CAT activity is shown in parentheses that was obtained with the trans-activating plasmid relative to the CAT activity obtained
with plasmid pHD1O1SVO DNA.
Evidently, the HIV sequences required for stimulation by the
HCMV IE region are not the same sequences required for
stimulation by tat.
S1 Nuclease Analysis of RNA in Transfected Cultures. To
assess the mechanism by which the HCMV IE region
trans-activates pHIV-CAT, we analyzed the RNA levels
specific for the CAT gene in transfected cells. A B-cell
lymphoma cell line (BJAB) was transfected with various
plasmid DNAs, then CAT assays were performed, and RNA
was isolated from each sample. Total cellular RNA was
hybridized with a uniformly 32P-labeled antisense RNA probe
synthesized by SP6 RNA polymerase. After S1 nuclease
digestion, nucleic acids were separated on a 6% acrylamide
gel containing 7 M urea. Nuclease-resistant RNA was de-
tected by autoradiography, and autoradiograms were
scanned by densitometry to determine the relative band
intensity.
The 370-base S1 nuclease-resistant probe fragment pro-
tected by hybridization to mRNA transcribed from pHIV-
CAT could be detected at a low level in samples isolated from
cells transfected with pHIV-CAT alone (Fig. 5). This band
intensity was increased >25-fold in samples transfected with
both pHIV-CAT and pHD1O1SV1. In addition, the samples
isolated from cells that were cotransfected with pBENN-2
DNA also have a higher concentration of CAT-specific RNA
(>100-fold increase over pHIV-CAT alone). In this particular
experiment the CAT activity directed by pHIV-CAT was
increased 25-fold by cotransfection with pHD1O1SV1 and
127-fold by cotransfection with pBENN-2. Thus, the trans-








FIG. 3. Effect ofHCMV IE region 1 gene products on the HCMV
IE promoter. HeLa cells were transfected with calcium phosphate-
precipitated plasmid DNA as in Fig. 2. The activity ofpHD1O1CAT2
decreased by a factor of 4 when cotransfected with pHD1O1SV1 and
by a factor of 6 when cotransfected with plasmid pHD1OlSV2.
trans-activators is accompanied by a concomitant increase in
pHIV-CAT mRNA.
DISCUSSION
In this report, we show that the IE gene region of the HCMV
strongly augments gene expression governed by the HIV
promoter. AIDS patients are frequently coinfected by
HCMV, and both HIV and HCMV can infect T lymphocytes.
Therefore, the ability of the HCMV to stimulate HIV-
directed gene expression may lead to important biologic
consequences in the HIV-infected individual.
The stimulation of pHIV-CAT activity by the HCMV IE
region is accompanied by a similar increase in the steady-
state level ofpHIV-CAT mRNA. We observe that the HCMV
IE region trans-activator functions at the level of increased
mRNA. At this point, however, we cannot distinguish wheth-
er the increased pHIV-CAT mRNA is the result of increased
transcriptional initiation or of increased mRNA stability. Our
data also show that the pBENN-2 plasmid, which encodes
the HIV tat, likewise appears to trans-activate primarily at
the level of increased mRNA. This finding is in agreement
with a report by Peterlin et al. (14) but conflicts with another
report (7) showing that HIV tat produces more stimulation at
the protein level than is seen at the level of mRNA. We find
that the HIV DNA sequences required for stimulation by tat
are not required for stimulation by the HCMV TE region. This
suggests that the HIV tat and the HCMV IE region are likely
as~mid DNA
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FIG. 4. Effect of HCMV IE region 2 gene products on the HIV
promoter. HeLa cells were transfected with calcium phosphate-
precipitated plasmid DNA as in Fig. 2. The stimulation ofpHIV-CAT
is 8-fold by cotransfection with plasmid pHD1O1SV3 and 95-fold by
cotransfection with plasmid pHD101-4.
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FIG. 5. S1 nuclease analysis of RNA in transfected cells. BJAB
cells, an Epstein-Barr virus-negative B-cell line (108 cells), were
electroporated with 20 ,ug of plasmid DNA. After 2 days, 10% of the
cells were removed for CAT assay, and total cellular RNA was
isolated from the remaining cells. Total cellular RNA (35 ,ug) was
hybridized to a 32P-labeled antisense RNA probe generated by SP6
polymerase, and the S1 nuclease-resistant material was electropho-
resed on a urea/acrylamide gel. The expected probe-protection
length is 370 base pairs. A, 12-hr exposure; B, 5-day exposure.
Lanes: a, molecular weight markers of 398 and 344 base pairs; b,
RNA from mock-transfection; c-e, RNA from cells transfected with
the following plasmids. Lanes: c, pHIV-CAT; d, pHIV-CAT plus
pBENN-2; e, pHIV-CAT plus pHD1O1SV1. In this experiment,
pHIV-CAT was stimulated 25-fold by pHD1O1SV1 and 150-fold by
pBENN-2. Laser densitometry scanning of the autoradiogram
showed a similar degree of stimulation at the mRNA level as
observed at the CAT level for both the pBENN-2 and pHD1O1SV1
trans-activators.
to trans-activate the HIV promoter using different mecha-
nisms.
The HCMV IE region appears to encode several different
proteins (8). Two plasmids that differ in the fourth exon of the
HCMV IE protein-coding sequence they carry have opposite
effects on gene expression downstream from target promot-
ers. Plasmid pHD1Q1SV2 encodes the major IE protein of
HCMV, and its product can down-regulate the major IE
promoter ofHCMV (Fig. 3); it has no effect on the HIV LTR.
Plasmid pHD101-4 encodes minor HCMV IE proteins, its
products do not affect the major IE promoter, but they can
trans-activate the LTR of HIV. These alternate exon se-
quences are arranged consecutively in the HCMV genome.
The minor HCMV IE proteins have not been observed,
although the RNAs have been observed in infected cells. The
major HCMV IE protein has been observed in infected cells
and in peripheral blood lymphocytes isolated from seropos-
itive people. We presume the minor IE proteins are present
in these cells also, and the trans-activation activity may
influence superinfecting virus. The role of these proteins in
HCMV-infected cells is unknown, but their function may be
analogous to that of the herpes simplex virus IE proteins,
which stimulate in trans the promoters of other herpes
simplex virus genes (15).
Several other DNA viruses including herpes simplex virus
1 have also been shown to trans-activate the HIV promoter
(16, 17). As we observed with HCMV, the herpes simplex
virus 1 IE region includes the trans-activating sequences.
However, the particular propensity ofAIDS patients to have
active HCMV infection makes the molecular interactions
between HCMV and HIV especially compelling. Biological-
lyj interactions between the causative agent of AIDS and
HCMV have been suggested even before the discovery of
HIV. In early publications describing AIDS, HCMV was
postulated as a possible causative agent (3, 18). Not only may
HIV infection reactivate HCMV through immunosuppres-
sion, but HCMV might directly affect the course of HIV
infection. HCMV infection itself causes changes in the ratio
of helper-to-suppressor T lymphocytes (19), and it has been
suggested (5) that progression of HIV infection to AIDS may
be influenced by a preexisting HCMV infection. Since we
show that there is a strong activation of the HIV LTR in
response to a HCMV IE function, at least two different
mechanisms, one molecular and the other immunologic, may
operate to influence the two infections.
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